Drug intelligence / Profile preview

fluocinolone acetonide + tazarotene

Development stage: Unknown
Modality: Small Molecules
Administration: Topical

Overview

A combination therapy that pairs fluocinolone acetonide, a corticosteroid, with tazarotene, a third-generation topical retinoid. This combination leverages complementary mechanisms of action to treat dermatological conditions, particularly psoriasis. The corticosteroid component provides anti-inflammatory effects and reduces irritation associated with tazarotene, while the retinoid normalizes keratinocyte differentiation and reverses hyperproliferation. Clinical studies show this combination provides greater efficacy, more rapid response, and superior tolerability compared to tazarotene monotherapy.

Targets

RARG (Retinoic acid receptor gamma)RARB (Retinoic acid receptor beta)GR (Glucocorticoid receptor)PLA2 (Phospholipase A2 group IID)

Beyond the preview

Go deeper on fluocinolone acetonide + tazarotene.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fluocinolone acetonide + tazarotene.

Explore the full profile